Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. - Wikidata - wikimedia - TriplyDB

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

http://www.wikidata.org/entity/Q34193514

about

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia Measurable residual disease testing in acute myeloid leukaemia.Future prospects of therapeutic clinical trials in acute myeloid leukemia.Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.Acute myeloid leukemia: 2014 update on risk-stratification and management.Management of older or unfit patients with acute myeloid leukemia Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.Randomized phase II trials: a long-term investment with promising returns Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment WT1/EGR1-mediated control of STIM1 expression and function in cancer cells Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.Acute myeloid leukemia in the real world: why population-based registries are needed.In silico model-based inference: an emerging approach for inverse problems in engineering better medicines Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.New considerations in the design of clinical trials for the treatment of acute leukemia.Physician's Attitude Towards Treatment of Older Patients and the Choice of Therapy Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin Curcumin Veto the Effects of Osteopontin (OPN) Specific Inhibitor on Leukemic Stem Cell Colony Forming Potential via Promotion of OPN Overexpression Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.How to manage high-risk acute myeloid leukemia.New agents for acute myeloid leukemia: is it time for targeted therapies?Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.Recent developments in management of older patients with acute myeloid leukemia.The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.

P2860

Q28087291-669A0BB3-866C-4616-B986-4ED7437E888B Q30234914-5DC2FDD0-8D2C-47A0-A95C-19B993164D2E Q30244168-0FA02D1C-C2C6-49A3-ACED-F0D365E80D63 Q30275229-FA4F0F48-C3A2-40A5-B72A-11141E3D0934 Q33752594-7ABE30B5-49A3-4C50-80AE-C6CB1C060CB3 Q33934665-03C94AA3-C10B-4CAC-8CD3-0BFC9CBBEEA9 Q34380060-9B45A4FC-7173-4406-8B30-0BCFA7DF5127 Q34665691-D0770FF0-087E-483C-8603-E41A7757C98A Q34893307-4F524993-A75C-4AAA-8F8B-FF226C8B228E Q34923690-2D207B1B-4CC3-4271-B0AC-A94F85A61D2A Q35115259-AE42ABBC-4F4E-46CB-94C6-0966D1261345 Q35124832-BC630F4E-B9FA-414F-8441-853E8D538925 Q35462617-82B5F69D-A11A-4CE4-90E7-58B900B170C6 Q35565648-8A368982-B067-4A7C-8036-D3F428145359 Q35575649-08460E0F-2D0A-4D72-B3E1-9F48D4AFCD9D Q35930622-09A01536-AF8A-46D7-B374-97824344A4B8 Q35980291-D80A0186-3FB5-4D13-A047-A8C2C6E0497C Q35984945-16CDB97F-9381-4810-A872-1A37FD334D30 Q36344469-E7BFB4F1-C9A7-498A-8C18-A7A162CD1126 Q36641721-A7306B1C-C9AA-41EC-A4BA-3E727426D7DD Q36826175-DF77E461-3C96-4947-9B78-D06BF4493E10 Q36932014-DCA656BA-8425-438F-95D3-BB1F97DAAF93 Q37144443-312DA24D-1709-44CE-B474-C17C6C74A92A Q37244802-D505CA5D-D610-4584-9505-0A82692C1746 Q37624593-397C6641-888B-47DF-A30E-42F6F8B28D4D Q37960820-37A7FEB6-6667-478D-A267-6DB6F072CC37 Q37973135-C1725D0D-2076-4B04-974E-8292921915FA Q40055082-DC3AE67A-A316-4B69-A889-FB8A925A4755 Q40395615-6C83CA4C-303D-4DBA-9D0B-C3E25A8F6593 Q41939573-B2428499-287C-4FD9-8284-EE40E5CDBE4E Q42149211-66624DCD-5BB8-47BB-B359-DAB73272B23A Q43089875-B23151C5-044C-4F7D-BF4A-E7F7A99FD5FB Q48256771-1901E965-0045-460E-8BA7-EC3556D005AC Q48332997-AE3C795F-9D8F-4AF6-BB7D-16106E8589D8

P2860

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

http://www.wikidata.org/entity/Q34193514

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@ast

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@en

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@nl

type

label

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@ast

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@en

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@nl

prefLabel

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@ast

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@en

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@nl

P1433

Q34193514-8D6FE700-313E-4120-90A7-18E784A7C6BB

P1476

Q34193514-8E532B0B-A867-4A50-A676-8BBEA2C7504D

P2093

Q34193514-298054D6-4065-4611-B62E-4828FC4063E2

Q34193514-45FEACC6-48A8-4853-809D-1B8A51419B0A

Q34193514-7042A391-15A7-47DE-9176-647D594D3948

Q34193514-BC95E3BB-E779-4113-B52E-3A8819FC661E

P2860

Q34193514-06B7F630-0199-43DA-875C-40DD9895D771

Q34193514-08568B51-FA36-4C68-9BCF-D01EFDC23649

Q34193514-0869A6D4-D3C4-47E9-9491-79D5C3992363

Q34193514-10A13491-9BFF-4F8C-9A55-46CBCD532541

Q34193514-116AF2F1-F61E-435F-8B85-A06357A00DA6

Q34193514-1306DB01-0EB8-4021-9154-840201D79929

Q34193514-16591948-1D68-462F-8EFE-776ADC1F8204

Q34193514-17101683-B022-4A83-A0D9-10C8988C5DE8

Q34193514-1EC2BBA9-6C97-4B97-96F0-C955CFF0FC52

Q34193514-2510B978-9AF2-4F4B-BC71-707BF02E4235

P304

Q34193514-F13DC5A4-EA5A-4200-B968-45E5AD836C11

P31

Q34193514-CCA6BCC8-C10B-4884-B6AD-743E099A867C

P356

Q34193514-13CFD935-FE3D-479F-9398-9BE96C2705BE

P407

Q34193514-FF7665DC-B266-4BC6-9F9A-62ED3E89DF13

P433

Q34193514-1CFEBD68-7640-4883-A22F-E40B803179DC

P478

Q34193514-145B1480-E6F4-4174-84DE-5F75219DCF64

P50

Q34193514-5EFE8598-E8C2-428A-82D3-03AA0A5AE3C0

Q34193514-95A9952F-947C-474A-8B6C-69822BC21415

P577

Q34193514-8B4CB33E-5732-4F0B-BADD-83F660691378

P5875

Q34193514-602E8DE5-B479-4CC1-BE61-19F0B69DA708

P698

Q34193514-872187E5-FC68-49AE-B9A7-3DF9E3642BAC

P921

Q34193514-7B87BA5D-D459-4A8C-99EF-54CF7296F8EB

P932

Q34193514-942A7BF2-DFFB-40AA-9476-919C13B4626C

P356

BLOOD-2010-05-285387

P1433

P1476

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

@en

P2093

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

Noel S Weiss

http://www.w3.org/2001/XMLSchema#string

Richard A Larson

http://www.w3.org/2001/XMLSchema#string

Roland B Walter

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Drug development cost estimates hard to swallow

Randomized, controlled trials, observational studies, and the hierarchy of research designs

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

The price of innovation: new estimates of drug development costs

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

Estimating the cost of new drug development: is it really 802 million dollars?

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Can the pharmaceutical industry reduce attrition rates?

P304

2420-2428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-05-285387

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Martin S Tallman

Frederick R. Appelbaum

P577

2010-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44664281

http://www.w3.org/2001/XMLSchema#string

P698

20538802

http://www.w3.org/2001/XMLSchema#string

P921

P932

2953881

http://www.w3.org/2001/XMLSchema#string